← FDA DRUG APPROVALS

FDA ANDA · ANDA210871

TOBRAMYCIN

Sponsor: LUOXIN AUROVITAS

APPLICATION
ANDA210871
TYPE
ANDA
ORIGINAL APPROVAL
2021-01-22
LATEST ACTION
2023-07-21
ROUTE
RESPIRATORY (INHALATION), INHALATION
DOSAGE FORM
SOLUTION
MARKETING STATUS
Discontinued

Products

TOBRAMYCINDiscontinued
TOBRAMYCIN 300MG/5ML · SOLUTION · INHALATION

Approval history

2023-07-21Labeling · Supplement 1 · standardAP
2021-01-22UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →